Indivumed partners with Flagship Biosciences

Create PDF

June 2019—Indivumed and Flagship Biosciences have announced a partnership in which the companies will offer a comprehensive set of services combining Flagship’s experience in biomarker development and Indivumed’s multiplex immunohistochemistry assay development capabilities. Indivumed’s client base will benefit from Flagship’s artificial intelligence–enabled computational tissue analysis digital pathology platform, which provides complimentary and comprehensive tissue profiling. The joint effort will expand Indivumed’s portfolio of services by providing CAP-accredited and CLIA-certified testing capabilities.